Background
ANDROMEDA was a phase III randomized open-label trial evaluating subcutaneous daratumumab (anti-CD38) plus bortezomib-cyclophosphamide-dexamethasone (VCd) versus VCd alone in newly diagnosed immunoglobulin light-chain (AL) amyloidosis. AL amyloidosis is a plasma cell disorder in which amyloid fibril deposition causes progressive organ damage (heart, kidneys, liver, nerves); rapid and deep hematologic response is critical to prevent irreversible organ damage. VCd was the established standard of care; ANDROMEDA tested whether daratumumab augmentation could achieve deeper and faster responses to improve organ outcomes.
Interventions and follow up
Arm A (VCd): Bortezomib 1.3 mg/m² + cyclophosphamide 300 mg/m² + dexamethasone weekly × 6 cycles (28-day cycles)
Arm B (D-VCd): Subcutaneous daratumumab 1800 mg + VCd × 6 cycles → daratumumab maintenance (q4w × up to 2 years)
Primary endpoint: Hematologic complete response (hCR) at 6 months per IMWG criteria
Secondary: organ response, major organ deterioration/PFS, OS
mFollow-up: 20.3 months
Arm B (D-VCd): Subcutaneous daratumumab 1800 mg + VCd × 6 cycles → daratumumab maintenance (q4w × up to 2 years)
Primary endpoint: Hematologic complete response (hCR) at 6 months per IMWG criteria
Secondary: organ response, major organ deterioration/PFS, OS
mFollow-up: 20.3 months
Results
hCR: 53.3% vs 18.1% (OR 5.1, 95% CI 3.2–8.2, P<.001)
Overall hematologic response: 92.3% vs 76.9%
Cardiac organ response: 41.5% vs 22.2%
Renal organ response: 53.0% vs 23.9%
Survival free from major organ deterioration or death: HR 0.58 (95% CI 0.42–0.80, P<.001)
Overall hematologic response: 92.3% vs 76.9%
Cardiac organ response: 41.5% vs 22.2%
Renal organ response: 53.0% vs 23.9%
Survival free from major organ deterioration or death: HR 0.58 (95% CI 0.42–0.80, P<.001)
Adverse events
Overall: Grade ≥3 AEs 43.3% vs 35.9%
Infusion-related: reactions 7.3% (Grade ≥3: 0.5%, mitigated by SC formulation)
Neurologic: peripheral neuropathy Grade ≥3 5.2% vs 4.7%
Cardiac: AEs similar between arms; 2 cardiac deaths each arm in cardiac stage IIIb patients — daratumumab contraindicated in Mayo stage IIIb (NT-proBNP ≥8500 pg/mL)
Infusion-related: reactions 7.3% (Grade ≥3: 0.5%, mitigated by SC formulation)
Neurologic: peripheral neuropathy Grade ≥3 5.2% vs 4.7%
Cardiac: AEs similar between arms; 2 cardiac deaths each arm in cardiac stage IIIb patients — daratumumab contraindicated in Mayo stage IIIb (NT-proBNP ≥8500 pg/mL)
Conclusions
Daratumumab SC added to VCd tripled the hematologic CR rate (53% vs 18%) and significantly improved cardiac and renal organ responses compared to VCd alone in newly diagnosed AL amyloidosis, establishing D-VCd as the standard of care for this organ-threatening plasma cell disorder.
Key Limitations
Open-label design; excluded Mayo Stage IIIb cardiac amyloidosis (highest-risk group — not eligible due to cardiac death safety signal in the daratumumab-amyloid experience); 6-month hCR as primary endpoint is a surrogate, though organ response and survival benefits are clinically meaningful; relatively short follow-up (20.3 months); SC daratumumab formulation (not IV) — ANDROMEDA was the pivotal trial for SC dara in AL amyloidosis; cyclophosphamide not universally used globally (some centers use melphalan-based combinations for transplant-ineligible); MRD assessments not incorporated into primary analyses.
Clinical Context
ANDROMEDA led to FDA approval of SC daratumumab (DARZALEX FASPRO) + VCd for AL amyloidosis in January 2021 — the first FDA approval specifically for AL amyloidosis. D-VCd is now preferred for newly diagnosed AL amyloidosis in eligible patients (excluding Mayo IIIb) per ASCO/ESMO and expert consensus. AL amyloidosis has historically lacked randomized trial evidence; ANDROMEDA fundamentally changed treatment practice. The SC formulation reduced administration time (3–5 min vs 3+ hours for IV), improving tolerability in this fragile patient population. Importantly, dara should not be used in Mayo Stage IIIb amyloidosis based on safety data showing early excess cardiac deaths.